Toxic Hepatitis mortality in Rio Grande do Sul and in its Macroregions of Health, analysis from 2006 to 2015
Keywords:Toxic hepatitis; Hepatotoxicity; DILI; Drug-induced liver injury; Rio Grande do Sul.
Objective: toxic hepatitis is any level of liver damage caused by drugs, medication or other substances. This research aims to describe the epidemiological profile of mortality from toxic hepatitis in the state of Rio Grande do Sul, Brazil, from 2006 to 2015. Methodology: we searched the DATASUS database looking for the number of deaths from toxic hepatitis and the total population from each region, for subsequent calculation of the death rate per 100,000 inhabitants. The analysis was divided in Health Macroregion (Valleys, South, Serra, North, Missioneira, Metropolitan and Midwest), year (2006 to 2015), sex (female and male) and age group (0-19, 20-59 and more than 60 years old). Results: a total of 31 male and 32 female deaths were identified. The difference between sexes was statistically significant (p=0.02). When comparing the 7 macroregions, Vales had the highest mortality rate and South the lowest (0.0796 and 0.0377, respectively). When comparing all macroregions per year there was no statistically significant difference (p=0.423). When comparing the age groups with the macroregions, the highest rates were found in the 60 or more years old group, but there was no statistically significant difference between the values found (p = 0.416). Conclusions: we found a significant predominance of mortality in the female population, new epidemiological studies are important to characterize the pattern of distribution of the disease in our environment and, consequently, to find new forms of assistance to the patients.
Amiot, T. D. C., Martínez, M. M., & Fresneda, J. L. G. (2012). Algunas consideraciones clinicopatogénicas de las hepatitis tóxicas. Medisan, 16(1), 127–134.
Barnhill, M. S., Real, M., & Lewis, J. H. (2018). Latest advances in diagnosing and predicting DILI: what was new in 2017? Expert Review of Gastroenterology and Hepatology, 12(10), 1033–1043. https://doi.org/10.1080/17474124.2018.1512854 (Barnhill, Real & Lewis, 2018)
Cano P., A., Cifuentes P., L., & Amariles, P. (2017). Structured literature review of hepatic toxicity caused by medicines. Revista Colombiana de Gastroenterologia, 32(4), 337–348. https://doi.org/10.22516/25007440.177
Danan, G., & Teschke, R. (2015). RUCAM in drug and herb induced liver injury: The update. International Journal of Molecular Sciences, 17(1), 1–33. https://doi.org/10.3390/ijms17010014
De Prado, N. M. B. L., Messias, G. C., Santos, G. O., Nunes, V. S., Schinonni, M. I., & Paraná, R. (2019). Prospective monitoring of drug use: Drug-induced liver injury in a primary healthcare center. Arquivos de Gastroenterologia, 56(4), 390–393. https://doi.org/10.1590/s0004-2803.201900000-73
Fisher, K., Vuppalanchi, R., & Saxena, R. (2015). Drug-induced liver injury. Archives of Pathology and Laboratory Medicine, 139(7), 876–887. https://doi.org/10.5858/arpa.2014-0214-RA
Goldman, L., & Schafer, A.I. (2014). Goldman-Cecil Medicina (24a ed.). Rio de Janeiro: Elsevier. 1120-1125
Hoofnagle, J. H., & Björnsson, E. S. (2019). Drug-induced liver injury - Types and phenotypes. New England Journal of Medicine, 381(3), 264–273. https://doi.org/10.1056/NEJMra1816149
Katarey, D., & Verma, S. (2016). Drug-induced liver injury. Clinical Medicine, 16(6), 104–109.
Larson, A. M. (2019). Drug-induced liver injury. Retrieved from https://www.uptodate.com/contents/drug-induced-liver-injury
Leise, M. D., Poterucha, J. J., & Talwalkar, J. A. (2014). Drug-induced liver injury. Mayo Clinic proceedings, 89(1), 95–106. https://doi.org/10.1016/j.mayocp.2013.09.016
Longo, D. L. & Fauci, A. S. (2015). Gastroenterologia e Hepatologia de Harrison (2a ed.). Porto Alegre: Artmed. 299-307
Robles-Díaz, M., Medina-Caliz, I., Stephens, C., Andrade, R. J., & Lucena, M. I. (2016). Biomarkers in DILI: One more step forward. Frontiers in Pharmacology, 7(AUG), 1–7. https://doi.org/10.3389/fphar.2016.00267
Teschke, R. (2019). Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019. Frontiers in Pharmacology, 10(July), 1–24. https://doi.org/10.3389/fphar.2019.00730
Zimmerman H. J. (2000). Drug-induced liver disease. Clinics in liver disease, 4(1), 73–vi. https://doi.org/10.1016/s1089-3261(05)70097-0
How to Cite
Copyright (c) 2020 Vinicius Rodrigues Pasetto; Ana Thereza Perin; Francisco Costa Beber Lemanski; Lara Beatriz Silva Golçalves; Agnes Grabrielle Wagner; Felipe Antônio Dal'Agnol; Leticia Reginato; Leonardo Sérgio Chiodi Mroginski; Paulo Roberto Reichert
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.